The analysis of the detection performance of nucleic acid testing and ELISA for HIV, HBV and HCB

摘要

Objective To explore the clinical efficacy of Nucleic acid testing (NAT) in combination with Enzyme linked immunosorbent assay (ELISA). Methods Between January 2015 and December 2016, 106,488 specimens from hospitalized patients were detected for HIV, HBV, and HCV by using NAT plus ELISA to compare the positive and negative coincidence rate in the same patient. Results 99.85% (106,324) HIV results, 94.80% (100,951) HBV results and 99.45% (105,902) HCV results were identical by both tests. The results, showing NAT+/ELISA?, for HIV, HBV, and HCV were 21, 316 and 0 respectively, and the results, showing NAT+/ELISA?, for HIV, HBV, and HCV were 143, 4958 and 586 respectively. Conclusions The combination of NAT and ELISA could effectively improve the detection accuracy and screening efficiency for HIV, HBV and HCV, decrease the rate of missed detection, and reduce the risk of iatrogenic infection.